Here are five things to know about the collaboration and new product:
1. The product will combine Bone Therapeutics’ allogeneic osteoblastic cell therapy product ALLOB with Kasio’s synthetic micro-granules bone substitute.
2. The project is subsidized by the government of the Walloon Region.
3. The two companies hope to offer a new approach to spinal fusion that will include:
• Osteoconduction
• Osteoinduction
• Osteogenesis
4. The combination of the ALLOB cells, which have already shown bone forming properties including osteoinduction and osteogenicity, with Kasios TCP’s osteoconductive micro-granules could enhance three-dimensional growth and bone growth in spinal fusion.
5. The technology could be particularly helpful in promoting osteoconduction for larger fracture areas that need more structural support.
More articles on orthopedic devices:
Exactech’s Equinoxe Shoulder System turns 10 years old
Baxano files for Chapter 11 bankruptcy protection; sells product lines
Zyga Technology enrolls 1st patient in Glyder Facet Restoration Device study
